10x Genomics (TXG) Non-Current Deffered Revenue (2018 - 2026)

10x Genomics (TXG) has 7 years of Non-Current Deffered Revenue data on file, last reported at $10.1 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deffered Revenue fell 19.34% year-over-year to $10.1 million; the trailing twelve-month figure through Mar 2026 stood at $10.1 million (down 19.34% YoY), and the FY2025 full-year result was $10.5 million, down 16.08% from the prior year.
• Non-Current Deffered Revenue fell to $10.1 million in Q1 2026, from $10.5 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $12.6 million in Q1 2025 to a low of $3.2 million in Q4 2022.
• A 5-year average of $10.3 million and a median of $10.9 million in 2025 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue soared 178.48% in 2023 and dropped 19.34% in 2026, its largest moves.
• Tracing TXG's Non-Current Deffered Revenue over 5 years: stood at $3.2 million in 2022, then soared by 178.48% to $8.8 million in 2023, then jumped by 41.97% to $12.5 million in 2024, then fell by 16.08% to $10.5 million in 2025, then retreated by 3.46% to $10.1 million in 2026.
• Business Quant data shows TXG's Non-Current Deffered Revenue at $10.1 million in Q1 2026, $10.5 million in Q4 2025, and $10.9 million in Q3 2025.